Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence.

Mark S SulkowskiAnnie F LuetkemeyerDavid L WylesClaudia MartorellAndrew MuirIlan WeisbergStuart C GordonRichard McLainGregory Huhn

Published in: Alimentary pharmacology & therapeutics (2020)

HCV treatment with DMP was accepted by patients and clinicians and may support HCV treatment outcomes among patients at high risk for treatment non-adherence (Clinical trials.gov NCT03164902).

Keyphrases

clinical trial
hepatitis c virus
end stage renal disease
type diabetes
chronic kidney disease
newly diagnosed
ejection fraction
adipose tissue
combination therapy
human immunodeficiency virus
metabolic syndrome
skeletal muscle
hiv infected
patient reported outcomes
antiretroviral therapy
double blind